Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 16, 2017 12:39:35 PM
Initiating Coverage June 26, 2017
http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Very Strong Insider & institutional Ownership:
Vivo Ventures LLC 16 012 808
Forward Ventures Services LLC 7 251 728
Technology Partners 7 050 691
Aspire Capital Partners LLC 2 791 666
Ernest Mario, PhD 1 844 328
Oppenheim Asset Management Services SARL 574 853
Medical Strategy GmbH 503 305
Palo Alto Investors LLC 423 738
Sabby Capital LLC 233 938
The Bollard Group LLC 192 217
Recent SLNO News
- Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome • GlobeNewswire Inc. • 06/28/2024 12:00:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/24/2024 09:18:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:52:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:51:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:50:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:29:59 PM
- Soleno Therapeutics Set to Join Russell 3000® Index • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 • GlobeNewswire Inc. • 05/22/2024 08:05:00 PM
- Soleno Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Soleno Therapeutics Stands with the Prader-Willi Syndrome Community • GlobeNewswire Inc. • 05/15/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:17 PM
- Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:28:56 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 08:58:44 PM
- Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock • GlobeNewswire Inc. • 05/03/2024 02:32:12 AM
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 05/02/2024 08:01:37 PM
- Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 08:05:00 PM
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/08/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:06:32 AM
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/31/2024 09:19:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:57:04 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM